Long-Term Safety and Efficacy Extension Study Of Autologous Adipose-Derived Mesenchymal Stem Cells JOINTSTEM in Patients With Knee Osteoarthiritis: A Phase III Extension Study
Latest Information Update: 11 Jul 2023
Price :
$35 *
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions; Registrational
- Sponsors R-Biopharm
- 26 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 16 Jun 2020 New trial record